About: Rethinking the role of hydroxychloroquine in the treatment of COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rethinking the role of hydroxychloroquine in the treatment of COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rethinking the role of hydroxychloroquine in the treatment of COVID‐19
Creator	Kim, Arthur Patrick, \| Callahan, Michael Meyerowitz, Eric Poznansky, Mark Friesen, Morgan Gelfand, Jeffrey Reeves, M Schoenfeld, Sara Vannier, Augustin
Source	Medline; PMC
abstract	There are currently no proven or approved treatments for coronavirus disease 2019 (COVID‐19). Early anecdotal reports and limited in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease. As an increasing number of patients with COVID‐19 are treated with these agents and more evidence accumulates, there continues to be no high‐quality clinical data showing a clear benefit of these agents for this disease. Moreover, these agents have the potential to cause harm, including a broad range of adverse events including serious cardiac side effects when combined with other agents. In addition, the known and potent immunomodulatory effects of these agents which support their use in the treatment of auto‐immune conditions, and provided a component in the original rationale for their use in patients with COVID‐19, may, in fact, undermine their utility in the context of the treatment of this respiratory viral infection. Specifically, the impact of HCQ on cytokine production and suppression of antigen presentation may have immunologic consequences that hamper innate and adaptive antiviral immune responses for patients with COVID‐19. Similarly, the reported in vitro inhibition of viral proliferation is largely derived from the blockade of viral fusion that initiates infection rather than the direct inhibition of viral replication as seen with nucleoside/tide analogs in other viral infections. Given these facts and the growing uncertainty about these agents for the treatment of COVID‐19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease. In this article, we review the datasets that support or detract from the use of these agents for the treatment of COVID‐19 and render a data informed opinion that they should only be used with caution and in the context of carefully thought out clinical trials, or on a case‐by‐case basis after rigorous consideration of the risks and benefits of this therapeutic approach.
has issue date	2020-04-29(xsd:dateTime)
bibo:doi	10.1096/fj.202000919
bibo:pmid	32350928
has license	cc-by-nc-nd
sha1sum (hex)	0e53702aaaf8233a26bcf408dff9674ded53f68a
schema:url	https://doi.org/10.1096/fj.202000919
resource representing a document's title	Rethinking the role of hydroxychloroquine in the treatment of COVID‐19
has PubMed Central identifier	PMC7267640
has PubMed identifier	32350928
schema:publication	FASEB J
resource representing a document's body	covid:0e53702aaaf8233a26bcf408dff9674ded53f68a#body_text
is schema:about of	named entity 'Creat' named entity 'USE' named entity 'COMMERCIAL' named entity 'non-commercial' named entity 'properly' named entity 'This' named entity 'hydroxychloroquine' named entity 'open access' named entity 'Commo' named entity 'COVID-19' named entity 'therapeutic agents' named entity 'virus' named entity 'IL-6' named entity 'HCQ' named entity 'diarrhea' named entity 'intravenous immunoglobulin' named entity '16.6' named entity 'immunology' named entity 'T-cell activation' named entity 'endosomal' named entity 'antimalarial agent' named entity 'animal models' named entity 'COVID' named entity 'immune modulation' named entity 'long-term' named entity 'pneumonia' named entity 'RT-PCR' named entity 'influenza' named entity 'immunomodulator' named entity 'neutralizing antibodies' named entity 'vaccination' named entity 'HCQ' named entity 'inoculated' named entity 'SARS-CoV-2' named entity 'cohort study' named entity 'China' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'HCQ' named entity 'HCQ' named entity 'COVID' named entity 'myositis' named entity 'anorexia' named entity 'mortality rate' named entity 'MHC' named entity 'immunomodulatory' named entity 'mortality rate' named entity 'fever' named entity 'COVID' named entity 'nausea' named entity 'antigen-presenting cells' named entity 'flu-like symptoms' named entity 'HCQ' named entity 'SARS-CoV-2' named entity 'long-term' named entity 'immune modulatory' named entity 'HCQ' named entity 'HCQ' named entity 'type I interferon' named entity 'infection' named entity 'toxicity' named entity 'randomized controlled trial' named entity 'Vero E6' named entity 'chloroquine' named entity 'health risk' named entity 'half-life' named entity 'seasonal influenza' named entity 'COVID' named entity 'Th17' named entity 'glycosylation' named entity 'thromboses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software